2 hours Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by HC Wainwright MarketBeat
HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Cytokinetics in a research note on Monday.
HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Cytokinetics in a research note on Monday.